Clinical Trial TitleA phase 2 study to evaluate the safety, tolerability and initial efficacy of pramipexole ER, given with aprepitant in patients with idiopathic Parkinson’s disease.
Clinical Trial Protocol Description:
To evaluate the safety/tolerability of pramipexole ER, when titrated to its clinically optimal dose or protocol-allowed maximal dose, given in combination with aprepitant, in patients with idiopathic Parkinson’s disease.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have signed an Institutional Review Board (IRB) approved informed consent document indicating that they understand the purpose of and procedures required by the study and are willing to participate in the study and comply with all study procedures and restrictions. Informed consent must be obtained from the patient and/or a designated representative prior to initiating screening procedures to evaluate eligibility of the study.
- Are a male or female, 40 – 80 years of age.
- Have a diagnosis of possible/probable idiopathic Parkinson’s disease (PD; Postuma RB, et al. 2015).
- Have PD severity in the Hoehn & Yahr 2 to 3 range.
This is a partial list of elgibility requirements.